Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

Fig. 1

Study design. aA sample size of approximately 614 patients was planned for enrollment; the actual number of patients randomized was 650. bIntravenous PF-06438179/GP1111 or infliximab-EU 3 mg/kg was given as an induction regimen at weeks 0, 2, and 6, followed by maintenance treatment with a 3 mg/kg dose starting at week 14 and continuing every 8 weeks thereafter. Dose escalation to 5 mg/kg PF-06438179/GP1111 or infliximab-EU was permitted at or after week 14 for patients with inadequate RA response. EOT End of treatment, Infliximab-EU Infliximab sourced from the European Union, RA Rheumatoid arthritis

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us